Chris Parker
Institute of Cancer Research
CancerInternal medicineRadiologyUrologySurgeryOncologyRandomized controlled trialHazard ratioPlaceboProstateProstatectomyProstate cancerRadium-223DocetaxelProstate-specific antigenGynecologyIn patientCastration resistantRadiation therapyMedicine
461Publications
83H-index
25.3kCitations
Publications 461
Newest
#1Kai Yun Ooi (The Royal Marsden NHS Foundation Trust)
#2Ian PereiraH-Index: 2
Last. Hina Saeed (MCW: Medical College of Wisconsin)H-Index: 4
view all 8 authors...
Abstract null null Background null Management of prostate cancer after surgery is controversial. Past studies on adjuvant radiotherapy (aRT) for higher-risk features have had conflicting results. Through the collaborative conversations of the global radiation oncology Twitter-based journal club (#RadOnc #JC), we explored this complex topic to share recent advances, better understand what the global radiation oncology community felt was important and inspire next steps. null null null Methods nul...
Source
Source
#4Laura Murphy (UCL: University College London)H-Index: 1
Source
#1John Staffurth (Cardiff University)H-Index: 34
#2Joanne S Haviland (ICR: Institute of Cancer Research)H-Index: 27
Last. Alison BirtleH-Index: 25
view all 20 authors...
Abstract null null Background null Moderate hypofractionation is the recommended standard of care for localised prostate cancer following the results of trials including Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy in Prostate Cancer (CHHiP). Evaluation of long-term patient-reported outcomes (PROs) is important to confirm safety and enhance patient information. null null null Objective null To determine whether 5-yr PROs from the CHHiP quality of life (QoL) substud...
Source
#1Chris Parker (ICR: Institute of Cancer Research)H-Index: 83
#2Paul SargosH-Index: 18
Last. Claire L Vale (UCL: University College London)H-Index: 25
view all 5 authors...
Source
#1Adham Hijab (The Royal Marsden NHS Foundation Trust)
#2Sebastian Curcean (The Royal Marsden NHS Foundation Trust)H-Index: 1
Last. Chris Parker (ICR: Institute of Cancer Research)H-Index: 83
view all 16 authors...
Abstract Background Radium-223 is a bone-seeking, alpha-emitting radionuclide used in metastatic castration resistant prostate cancer (mCRPC). Radium-223 increases the risk of fracture when used in combination with abiraterone and prednisolone. The risk of fracture in men receiving radium-223 monotherapy is unclear. Patients and Methods Prospective, multicentre phase II study of radium-223 in 36 men with mCRPC, and a reference cohort (n=36), matched for fracture risk, not treated with radium-223...
Source
2 CitationsSource
#1Adnan Ali (University of Manchester)H-Index: 7
#2Alex HoyleH-Index: 6
Last. Noel W. ClarkeH-Index: 71
view all 17 authors...
Importance Prostate radiotherapy (RT) improves survival in men with low-burden metastatic prostate cancer. However, owing to the dichotomized nature of metastatic burden criteria, it is not clear how this benefit varies with bone metastasis counts and metastatic site. Objective To evaluate the association of bone metastasis count and location with survival benefit from prostate RT. Design, setting, and participants This exploratory analysis of treatment outcomes based on metastatic site and exte...
4 CitationsSource
#1William A. Hall (MCW: Medical College of Wisconsin)H-Index: 23
#2Alison Tree (The Royal Marsden NHS Foundation Trust)H-Index: 20
Last. Colleen A. Lawton (MCW: Medical College of Wisconsin)H-Index: 61
view all 7 authors...
5 CitationsSource
#1Vasilis Stavrinides (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 7
#2Tom Syer (UCL: University College London)H-Index: 1
Last. Mark Emberton (UCLH: University College London Hospitals NHS Foundation Trust)H-Index: 80
view all 30 authors...
BACKGROUND False positive multiparametric magnetic resonance imaging (mpMRI) phenotypes prompt unnecessary biopsies. The Prostate MRI Imaging Study (PROMIS) provides a unique opportunity to explore such phenotypes in biopsy-naive men with raised prostate-specific antigen (PSA) and suspected cancer. OBJECTIVE To compare mpMRI lesions in men with/without significant cancer on transperineal mapping biopsy (TPM). DESIGN, SETTING, AND PARTICIPANTS PROMIS participants (n=235) underwent mpMRI followed ...
2 CitationsSource